AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27266507 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 488
Study 27266507 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic vascular resistance
Number of subjects: 488
Study 27266697 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole treatment (400 mg administered once every 3 months for 12 months)
Number of subjects: 700
Study 27266697 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (administered once every 3 months for 12 months)
Number of subjects: 700
Study 27266702 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax ginseng and salvia miltiorrhiza supplementation
Number of subjects: 23
Study 27266702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 27266721 — intervention group
Group type: EXPERIMENTAL
Intervention: Tac-OD dosing based on CYP3A5 genotypes: 0.20 mg/kg/day for CYP3A5*3/*3, 0.25 mg/kg/day for CYP3A5*3/*3, 0.30 mg/kg/day for CYP3A5*1/*3, 0.35 mg/kg/day for CYP3A5*1/*1.
Number of subjects: 151
Study 27266721 — intervention group
Group type: EXPERIMENTAL
Intervention: Tac-OD dosing based on CYP3A5 genotypes.
Number of subjects: 151
Study 27266721 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified Tac-OD strategy.
Number of subjects: 151
Study 27267105 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide plus low-dose dexamethasone (POM + LoDEX)
Number of subjects: 3
Study 27267107 — intervention group
Group type: EXPERIMENTAL
Intervention: cf-PWV determined using the SphygmoCor System
Number of subjects: 500
Study 27267107 — intervention group
Group type: EXPERIMENTAL
Intervention: CAVI estimated using VASERA
Number of subjects: 500
Study 27267107 — intervention group
Group type: EXPERIMENTAL
Intervention: telomere length
Number of subjects: 500
Study 27267107 — intervention group
Group type: EXPERIMENTAL
Intervention: carotid intima-media thickness
Number of subjects: 500
Study 27267107 — intervention group
Group type: EXPERIMENTAL
Intervention: central and peripheral augmentation index
Number of subjects: 500
Study 27267107 — intervention group
Group type: EXPERIMENTAL
Intervention: ankle-brachial pulse wave velocity
Number of subjects: 500
Study 27267107 — intervention group
Group type: EXPERIMENTAL
Intervention: ankle-brachial index
Number of subjects: 500
Study 27267107 — intervention group
Group type: EXPERIMENTAL
Intervention: retinal arteriovenous index
Number of subjects: 500
Study 27267107 — intervention group
Group type: EXPERIMENTAL
Intervention: renal and cardiac organ damage
Number of subjects: 500
Study 27267107 — intervention group
Group type: EXPERIMENTAL
Intervention: lifestyles (physical activity, adherence to the Mediterranean diet, alcohol and tobacco consumption)
Number of subjects: 500
Study 27267107 — intervention group
Group type: EXPERIMENTAL
Intervention: psychological factors (depression, anxiety and chronic stress)
Number of subjects: 500
Study 27267107 — intervention group
Group type: EXPERIMENTAL
Intervention: inflammatory factors and oxidative stress
Number of subjects: 500
Study 27267182 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment group (Group A) with physical, occupational, speech-language or other conventional rehabilitation therapies.
Number of subjects: 300
Study 27267182 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment group (Group B) with traditional Korean medicine interventions (herbal medicine, chuna, moxibustion, and acupuncture) in addition to conventional treatment.
Number of subjects: 300
Study 27267254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (140 mg, single oral dose)
Number of subjects: 40
Study 27267254 — intervention group
Group type: COMPARATOR
Intervention: Healthy control (n=6)
Number of subjects: 40
Study 27267549 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncomplicated acute appendicitis
Number of subjects: 705
Study 27267549 — intervention group
Group type: COMPARATOR
Intervention: Complicated acute appendicitis (CA2)
Number of subjects: 705
Study 27267608 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg every 2 weeks until progression
Number of subjects: 36
Study 27267608 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 36
Study 27267887 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and support for Screening and Brief Interventions (SBI)
Number of subjects: 68
Study 27267887 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial reimbursement
Number of subjects: 68
Study 27267887 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based method of delivering advice on SBI
Number of subjects: 68
Study 27267887 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies for SBI
Number of subjects: 68
Study 27267887 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent exposure of SBI in media and guidelines
Number of subjects: 68
Study 27267887 — intervention group
Group type: EXPERIMENTAL
Intervention: SBI facilitating information systems and protocol-led care
Number of subjects: 68
Study 27267942 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary lactate measurement on admission
Number of subjects: 120
Study 27267942 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary lactate measurement
Number of subjects: 120
Study 27268271 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial Length (AL)
Number of subjects: 218
Study 27268271 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior Chamber Depth (ACD)
Number of subjects: 218
Study 27268271 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior Chamber Volume (ACV)
Number of subjects: 218
Study 27268271 — intervention group
Group type: EXPERIMENTAL
Intervention: Spherical Equivalent
Number of subjects: 218
Study 27268271 — intervention group
Group type: EXPERIMENTAL
Intervention: Accommodation
Number of subjects: 218
Study 27268271 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast Sensitivity (AULCSF)
Number of subjects: 218
Study 27268271 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractive Correction Change
Number of subjects: 218
Study 27268471 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking activities
Number of subjects: 42
Study 27268471 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonwalking activities
Number of subjects: 42
Study 27268471 — intervention group
Group type: EXPERIMENTAL
Intervention: Short walks
Number of subjects: 42
Study 27268471 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall physical activity
Number of subjects: 42
Study 27268499 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mallampati classification
Number of subjects: 243
Study 27268499 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper lip bite test
Number of subjects: 243
Study 27268499 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth opening
Number of subjects: 243
Study 27268499 — intervention group
Group type: EXPERIMENTAL
Intervention: Height to thyromental distance (HT/TMD)
Number of subjects: 243
Study 27268499 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck circumference to thyromental distance (NC/TMD)
Number of subjects: 243
Study 27268499 — intervention group
Group type: EXPERIMENTAL
Intervention: LEMON model
Number of subjects: 243
Study 27268499 — intervention group
Group type: EXPERIMENTAL
Intervention: Naguib model
Number of subjects: 243
Study 27268499 — intervention group
Group type: EXPERIMENTAL
Intervention: POGO score
Number of subjects: 243
Study 27268499 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall predictive airway assessment tests
Number of subjects: 243
Study 27269295 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg every 4 weeks for 4 months (2 mg/kg for those ≤40 kg)
Number of subjects: 20
Study 27269295 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab reintroduced on relapse, administered every 4 weeks (increased to every 8 weeks) for 24 months
Number of subjects: 20
Study 27269295 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab treatment
Number of subjects: 20
Study 27269940 — intervention group
Group type: EXPERIMENTAL
Intervention: MART1-specific CTLs followed by anti-CTLA-4 (ipilimumab)
Number of subjects: 10
Study 27269940 — intervention group
Group type: COMPARATOR
Intervention: ipilimumab monotherapy
Number of subjects: 10
Study 27269945 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutropenic diet and social restrictions (food, social contacts, pets)
Number of subjects: 339
Study 27269945 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, weight group, risk stratification, and nonabsorbable antibiotics
Number of subjects: 339
Study 27269947 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (1 or 3 mg/kg every 2 weeks)
Number of subjects: 81
Study 27270171 — intervention group
Group type: EXPERIMENTAL
Intervention: Centripetal lesions with persistent phase rim
Number of subjects: 17
Study 27270171 — intervention group
Group type: COMPARATOR
Intervention: Centripetal lesions with transient phase rim
Number of subjects: 17
Study 27270171 — intervention group
Group type: COMPARATOR
Intervention: Centrifugal lesions
Number of subjects: 17
Study 27270177 — intervention group
Group type: EXPERIMENTAL
Intervention: κ.CARTs
Number of subjects: 16
Study 27270475 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (75-g) and three isocaloric and isovolemic liquid meals with low, medium, and high fat content.
Number of subjects: 30
Study 27270566 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia
Number of subjects: 18
Study 27270566 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA infusion
Number of subjects: 18
Study 27270566 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac
Number of subjects: 18
Study 27270566 — intervention group
Group type: EXPERIMENTAL
Intervention: Flicker stimulation
Number of subjects: 18
Study 27271157 — intervention group
Group type: EXPERIMENTAL
Intervention: ActiMyo® device
Number of subjects: 7
Study 27271181 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin Therapy
Number of subjects: 0
Study 27271181 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 27271182 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-and-Night Closed-Loop Control using the Unified Safety System
Number of subjects: 0
Study 27271191 — intervention group
Group type: EXPERIMENTAL
Intervention: Offspring of women with type 1 diabetes
Number of subjects: 277
Study 27271191 — intervention group
Group type: COMPARATOR
Intervention: Control group from the background population
Number of subjects: 277
Study 27271455 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive Parenting (RP) intervention
Number of subjects: 291
Study 27271455 — intervention group
Group type: COMPARATOR
Intervention: Control group (developmentally appropriate home safety intervention)
Number of subjects: 291
Study 27271730 — intervention group
Group type: EXPERIMENTAL
Intervention: AASPIRE Healthcare toolkit including the Autism Healthcare Accommodations Tool (AHAT)
Number of subjects: 259
Study 27272171 — intervention group
Group type: COMPARATOR
Intervention: ABT-494 single dose (1-48 mg)
Number of subjects: 114
Study 27272171 — intervention group
Group type: COMPARATOR
Intervention: ABT-494 multiple dose (3-24 mg twice daily for 14 days)
Number of subjects: 114
Study 27272171 — intervention group
Group type: COMPARATOR
Intervention: ABT-494 multiple dose (3-24 mg twice daily for 27 days) in RA subjects
Number of subjects: 114
Study 27272279 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 (IV) 50 kBq/kg
Number of subjects: 6
Study 27272279 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 (IV) 100 kBq/kg
Number of subjects: 6
Study 27272279 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 (IV)
Number of subjects: 6
Study 27272748 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette users
Number of subjects: 932
Study 27272748 — intervention group
Group type: COMPARATOR
Intervention: Tobacco smokers
Number of subjects: 932
Study 27272748 — intervention group
Group type: COMPARATOR
Intervention: Dual users
Number of subjects: 932
Study 27272748 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 932
Study 27272748 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual users continuing or converting from tobacco smoking to dual use
Number of subjects: 932
Study 27273066 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based mastery learning (SBML)
Number of subjects: 112
Study 27273066 — intervention group
Group type: COMPARATOR
Intervention: Traditionally trained residents
Number of subjects: 112
Study 27273066 — intervention group
Group type: COMPARATOR
Intervention: Hospitalist physicians
Number of subjects: 112
Study 27273066 — intervention group
Group type: EXPERIMENTAL
Intervention: SBML-trained residents
Number of subjects: 112
Study 27273748 — intervention group
Group type: EXPERIMENTAL
Intervention: Large bottle (≥6 oz)
Number of subjects: 386
Study 27273748 — intervention group
Group type: COMPARATOR
Intervention: Regular bottle (<6 oz)
Number of subjects: 386
Study 27273860 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose intravenous rtPA (0.9mg/kg)
Number of subjects: 40
Study 27275632 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified FOLFIRINOX treatment (85 mg/m2 of oxaliplatin, 180 mg/m2 of irinotecan hydrochloride, 400 mg/m2 of leucovorin calcium, and 2400 mg/m2 of 5-fluorouracil for 4 cycles) followed by 5.5 weeks of external-beam radiation (50.4 Gy delivered in 28 daily fractions) with capecitabine (825 mg/m2 orally twice daily) prior to pancreatectomy.
Number of subjects: 22
Study 27276397 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous hydrodiscectomy
Number of subjects: 40
Study 27276397 — intervention group
Group type: COMPARATOR
Intervention: Open microdiscectomy
Number of subjects: 40
Study 27276526 — intervention group
Group type: EXPERIMENTAL
Intervention: Striatum involvement in anxiety circuitry
Number of subjects: 0
Study 27276526 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral processes related to anxiety
Number of subjects: 0
Study 27276526 — intervention group
Group type: EXPERIMENTAL
Intervention: Schematic representation of anxiety circuitry
Number of subjects: 0
Study 27276561 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 1540
Study 27278468 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise program
Number of subjects: 30
Study 27278794 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza respiratory disease broadly defined
Number of subjects: 28516
Study 27278794 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza B hospitalisations
Number of subjects: 28516
Study 27278794 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza prevention or early intervention with anti-viral treatment
Number of subjects: 28516
Study 27278794 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent seasonal influenza vaccination
Number of subjects: 28516
Study 27279247 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal glucose administration
Number of subjects: 13
Study 27279247 — intervention group
Group type: COMPARATOR
Intervention: Gastric glucose administration
Number of subjects: 13
Study 27280017 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants (specific type not mentioned, but includes vitamin K antagonists such as warfarin and newer drugs like Xa and thrombin inhibitors)
Number of subjects: 0
Study 27280017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27280505 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal wall reconstruction (AWR)
Number of subjects: 18
Study 27280505 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with intact abdominal wall undergoing colorectal resection)
Number of subjects: 18
Study 27280591 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO growth standards/references
Number of subjects: 5996
Study 27280591 — intervention group
Group type: COMPARATOR
Intervention: National growth references
Number of subjects: 5996
Study 27280802 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilayer Flow Modulator (MFM)
Number of subjects: 23
Study 27280963 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50-100mg/day for 8 weeks
Number of subjects: 36
Study 27281556 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole with lapatinib
Number of subjects: 821
Study 27281556 — intervention group
Group type: COMPARATOR
Intervention: Letrozole monotherapy
Number of subjects: 821
Study 27281556 — intervention group
Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 821
Study 27281773 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT-imaged subclinical arterial inflammation
Number of subjects: 44
Study 27281773 — intervention group
Group type: EXPERIMENTAL
Intervention: TBR of each separate segment
Number of subjects: 44
Study 27281773 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple linear regression model including age, sex, BMI, hemoglobin A1c (HbA1c), hs-CRP, cholesterol, cSBP, and PWV
Number of subjects: 44
Study 27281793 — intervention group
Group type: EXPERIMENTAL
Intervention: eltrombopag
Number of subjects: 21
Study 27281793 — intervention group
Group type: EXPERIMENTAL
Intervention: romiplostim
Number of subjects: 21
Study 27282141 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular endothelial growth factor (VEGF)
Number of subjects: 31
Study 27282141 — intervention group
Group type: EXPERIMENTAL
Intervention: Eotaxin
Number of subjects: 31
Study 27282141 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor alpha (TNF-α)
Number of subjects: 31
Study 27282141 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-γ (IFN-γ)
Number of subjects: 31
Study 27282141 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrophage inflammatory protein-1α (MIP-1α)
Number of subjects: 31
Study 27282289 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 24 hours before chemotherapy
Number of subjects: 20
Study 27282289 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 48 hours before chemotherapy
Number of subjects: 20
Study 27282289 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 72 hours before chemotherapy
Number of subjects: 20
Study 27282431 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced implementation strategy
Number of subjects: 345
Study 27282431 — intervention group
Group type: COMPARATOR
Intervention: Basic implementation strategy
Number of subjects: 345
Study 27282451 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic algorithm for pre-operative prediction of anastomotic leakage (AL) risk using inflammatory, immune-related, and genetic parameters.
Number of subjects: 588
Study 27282451 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative diagnostic algorithm for anastomotic leakage (AL).
Number of subjects: 588
Study 27282451 — intervention group
Group type: COMPARATOR
Intervention: Patients developing anastomotic leakage (AL) post-surgery (estimated 8-10%).
Number of subjects: 588
Study 27282601 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting bioresorbable vascular scaffold (BVS)
Number of subjects: 35
Study 27282899 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive fractional flow reserve (FFR)
Number of subjects: 0
Study 27282899 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive coronary flow reserve (CFR)
Number of subjects: 0
Study 27282899 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 0
Study 27282899 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonepicardial disease and diffuse atherosclerosis
Number of subjects: 0
Study 27282998 — intervention group
Group type: EXPERIMENTAL
Intervention: FCGR3A VV genotype
Number of subjects: 1134
Study 27282998 — intervention group
Group type: EXPERIMENTAL
Intervention: FCGR3A VF genotype
Number of subjects: 1134
Study 27282998 — intervention group
Group type: EXPERIMENTAL
Intervention: FCGR3A FF genotype
Number of subjects: 1134
Study 27282998 — intervention group
Group type: EXPERIMENTAL
Intervention: FCGR2A (per R allele)
Number of subjects: 1134
Study 27282998 — intervention group
Group type: EXPERIMENTAL
Intervention: FCGRIIA RR genotype
Number of subjects: 1134
Study 27283860 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib (150 mg twice daily) plus trametinib (2 mg once daily)
Number of subjects: 57
Study 27283860 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib
Number of subjects: 57
Study 27284271 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated compression stockings (GCS) plus anticoagulation (edoxaban or enoxaparin)
Number of subjects: 0
Study 27284271 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation alone (edoxaban or enoxaparin)
Number of subjects: 0
Study 27284271 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation plus GCS
Number of subjects: 0
Study 27284271 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation alone
Number of subjects: 0
Study 27285281 — intervention group
Group type: EXPERIMENTAL
Intervention: PankoMab-GEX (1-2200 mg, Q3W, Q2W, QW)
Number of subjects: 74
Study 27285281 — intervention group
Group type: EXPERIMENTAL
Intervention: PankoMab-GEX (≥1700 mg Q3W)
Number of subjects: 74
Study 27285281 — intervention group
Group type: EXPERIMENTAL
Intervention: PankoMab-GEX
Number of subjects: 74
Study 27285281 — intervention group
Group type: EXPERIMENTAL
Intervention: PankoMab-GEX (≥700 mg over 3 weeks)
Number of subjects: 74
Study 27285295 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI-SDS reduction of 0.25-0.5
Number of subjects: 1388
Study 27285295 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI-SDS reduction greater than 0.5
Number of subjects: 1388
Study 27285295 — intervention group
Group type: EXPERIMENTAL
Intervention: Per 0.1 BMI-SDS reduction
Number of subjects: 1388
Study 27286368 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolarity Index (BPx)
Number of subjects: 615
Study 27286790 — intervention group
Group type: EXPERIMENTAL
Intervention: BEZ235 (400 mg b.i.d.)
Number of subjects: 10
Study 27286790 — intervention group
Group type: EXPERIMENTAL
Intervention: BEZ235 (200 mg b.i.d.)
Number of subjects: 10
Study 27286790 — intervention group
Group type: EXPERIMENTAL
Intervention: BEZ235 (300 mg b.i.d.)
Number of subjects: 10
Study 27286790 — intervention group
Group type: EXPERIMENTAL
Intervention: BEZ235 (all doses)
Number of subjects: 10
Study 27287231 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 85
Study 27287512 — intervention group
Group type: EXPERIMENTAL
Intervention: ONCOS-102 (Ad5/3-D24-GM-CSF)
Number of subjects: 0